0001209191-23-002193.txt : 20230105 0001209191-23-002193.hdr.sgml : 20230105 20230105211443 ACCESSION NUMBER: 0001209191-23-002193 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keen Nicholas CENTRAL INDEX KEY: 0001776881 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 23513516 MAIL ADDRESS: STREET 1: C/O BICYCLE THEAPEUTICS LIMITED STREET 2: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-03 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001776881 Keen Nicholas C/O BICYCLE THERAPEUTICS PLC BLOCKS A & B, PORTWAY BUILDING CAMBRIDGE X0 CB21 6GS UNITED KINGDOM 0 1 0 0 Chief Scientific Officer Ordinary Shares 2023-01-03 4 A 0 17500 0.00 A 40977 D Ordinary Shares 2023-01-03 4 S 0 1817 29.06 D 39160 D Ordinary Shares 7000 I By GRAT Employee Stock Option (right to buy) 29.60 2023-01-03 4 A 0 35000 0.00 A 2033-01-03 Ordinary Shares 35000 35000 D Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. Each RSU represents a contingent right to receive one ordinary share. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. /s/ Lee Kalowski, Attorney-in-Fact 2023-01-05